The business unit Vifor Pharma Rx develops and manufactures pharmaceutical products mainly for the therapeutic fields of

_iron deficiency anaemia
_nephrology
_autoimmune diseases

Iron deficiency anaemia is the most widespread deficiency worldwide and ranks among the 20 greatest health risk factors for humanity according to the World Health Organisation (WHO). With its range of intravenous and oral iron supplements Vifor Pharma plays a global leading role.

The most important products of the business unit Vifor Pharma Rx:

Venofer^® (iron sucrose) is an intravenous (i.v.) product for the treatment of iron deficiency mainly used in haemodialysis. Venofer^® is the leading i.v. iron product worldwide and accepted as gold standard in dialysis. For more information visit www.venofer.com.

Ferinject^® (ferric carboxymaltose) is an innovative iron replacement product for the i.v. treatment of iron deficiency. The product is approved for registration in 18 EU countries and in Switzerland and was launched in November 2007. The product has a huge potential in a wide range of therapeutic areas: With Ferinject^® Vifor Pharma aims to develop the i.v. iron market beyond haemodialysis into new indications such as gynaecology, chronic kidney disease (CKD), chemotherapy-induced anaemia (CIA) and inflammatory bowel disease (IBD).

Maltofer^® (iron polymaltose) is an oral iron replacement product for the treatment of iron deficiency. The product offers the patient a long-term treatment due to its safety and tolerability profile.

CellCept is a drug developed and marketed by Roche for the treatment of rejection reactions following organ transplants. Thanks to the acquisition of Aspreva in 2008 Vifor Pharma today has specific know-how in the field of autoimmune diseases at its command. These competences are applied to develop CellCept for different autoimmune indications. Click here for more information.

Phosphate binder PA21 is a new product currently under development at Vifor Pharma. PA 21 is due to bind excess phosphate in the blood, thereby aiding phosphate excretion. It is intended to be used particularly in haemodialysis patients. The regulatory filling is anticipated for 2011.